In the less than two months since becoming the first drug developer to receive Food and Drug Administration clearance for a NASH treatment, Madrigal Pharmaceuticals has been hard at work.

To this end, the Conshohocken-based company’s first product, Rezdiffra, has received marketing clearance from the FDA as a treatment for NASH patients with moderate to advanced liver scarring, writes John George for the Philadelphia Business Journal. 

Nash, which stands for nonalcoholic steatohepatitis, is a fatty liver disease characterized by inflammation of the liver. The condition causes fibrosis scar tissue to build up on the liver, which can lead to liver failure and the need for a liver transplant.

Madrigal CEO Bill Sibold said the company is initially focused on reaching the 315,000 NASH patients diagnosed with significant fibrosis.

Meanwhile, the sales team is targeting its educational efforts on the 5,000 to 7,000 specialists about all aspects of the medication.

“[Rezdiffra] is the first product ever in the space where there’s a huge unmet need, but the reality is there’s never been a prescription medicine for NASH before, so it takes time to create the pathways for patients to find their way to a [physician] practice,” Sibold said.

Read more about Madrigal’s groundbreaking drug, Rezdiffra, at the Philadelphia Business Journal.

_____